Stock comparison
Krystal Biotech
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
KRYS
Krystal Biotech
Market cap
$8.83B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | KRYS | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 51C | 77B | LMAT |
| Benjamin Graham | 74D | 89A | LMAT |
| Philip Fisher | 74C | 81C | LMAT |
| Peter Lynch | 58C | 67B | LMAT |
| Joel Greenblatt | 59C | 56D | KRYS |
| Charlie Munger | 64D | 68D | LMAT |
| Terry Smith | 64D | 69D | LMAT |
Side-by-side metrics
| Metric | KRYS | LMAT |
|---|---|---|
| Market cap | $8.83B | $2.23B |
| P/E (TTM) | 39.9x | 37.1x |
| EV/EBIT | 52.9x | 36.6x |
| ROIC (TTM) | 13.85% | 9.43% |
| Gross margin | 92.79% | 72.39% |
| Net margin | 53.92% | 24.35% |
| Revenue CAGR 5y | - | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.0x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
KRYS leads on
- Debt / Equity0.0xvs 0.5x+100%
- Market cap$8.83Bvs $2.23B+75%
- Net margin53.92%vs 24.35%+55%
- ROIC (TTM)13.85%vs 9.43%+32%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- EV/EBIT36.6xvs 52.9x+31%
- P/E (TTM)37.1xvs 39.9x+7%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.